Navigation Links
Genmab Announces Encouraging Preclinical Data for ofatumumab
Date:9/7/2007

Summary: Genmab Announces ofatumumab Appeared More Effective Than rituximab

in a Pre-Clinical Study

COPENHAGEN, Denmark, September 7 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more effective at inducing complement dependent cytotoxicity (CDC), an immune system killing mechanism, than rituximab in a pre-clinical study. The CD20 antibodies were incubated with tumor cells and analyzed using Spinning Disk Confocal Fluorescent Microscopy. This technology allows imaging of the effects on target cells induced by therapeutic antibodies in real time. Both antibodies were found to activate CDC and induced profound changes in both shape and appearance of target cells.

Direct comparisons of ofatumumab and rituximab revealed ofatumumab to induce much more rapid and profound CDC and far more impressive cell changes than rituximab. This, furthermore, lead to more effective killing of target cells by ofatumumab.

"This study supports the growing body of pre-clinical research that suggests ofatumumab may be more effective in eliminating target cells and treating diseases such as lymphoid cancers and rheumatoid arthritis than existing therapies," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

These pre-clinical data will be presented in an oral presentation at the XIth European Meeting on Complement in Human Disease, in Cardiff, United Kingdom on September 9, 2007.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

Stock Exchange Release no. 37/2007


'/>"/>
SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... San Diego, CA (PRWEB) , ... May 04, ... ... Mother’s Day? Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking ... everything you need to give mom an experience she won’t forget. , Guests ...
(Date:5/4/2016)... ... , ... Proove Biosciences, Inc. , the commercial and research leader in ... . The partnership is designed to advance research in pain genetics in an effort ... With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda ...
(Date:5/4/2016)... WHIPPANY, N.J. , May 4, 2016 /PRNewswire/ ... evaluating its oncology compound Stivarga ® (regorafenib) ... hepatocellular carcinoma (HCC) has met its primary endpoint ... The study, called RESORCE, evaluated the efficacy and ... disease has progressed after treatment with sorafenib. The ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, 2016 , ... ... neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the ... treatment or cure. , Through numerous community events held during the month of May, ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):